10-Q: Bio-Techne Reports 9% Increase in Q2 Net Sales Driven by Diagnostics and Spatial Biology Growth

Bio-Techne Corporation reports a 9% increase in net sales for the second quarter of fiscal year 2025, driven by strong performance in its Diagnostics and Spatial Biology segment and improving biopharma market conditions.

Summary

• Bio-Techne Corporation's Q2 2025 net sales increased by 9% to $297.0 million compared to $272.6 million in Q2 2024.
• Organic revenue grew by 9% in Q2 2025.
• Net earnings for Q2 2025 increased to $34.9 million from $27.5 million in Q2 2024, primarily due to favorable volume leverage and a non-recurring prior year impairment of a business held-for-sale.
• For the six months ended December 31, 2024, net sales increased by 7% to $586.5 million compared to $549.5 million in the same period last year.
• Net earnings for the six months decreased to $68.5 million from $78.5 million in the prior year, primarily due to restructuring and restructuring-related costs.
• The Protein Sciences segment saw a 7% increase in net sales for Q2 2025 and 3% for the six months ended December 31, 2024.
• The Diagnostics and Spatial Biology segment experienced a 12% increase in net sales for both Q2 2025 and the six months ended December 31, 2024.
• The company's effective income tax rate was 18.6% for Q2 2025 and 17.5% for the six months ended December 31, 2024.
• The company expects capital expenditures for the remainder of fiscal 2025 to be approximately $20 million.
• The company declared a cash dividend of $0.08 per share payable February 28, 2025.

Sentiment

Score: 7

Explanation: The report presents a generally positive outlook, with increased net sales and organic revenue growth. While net earnings decreased for the six-month period due to restructuring costs, the company's strategic investments and growth in key segments suggest a positive trajectory.

Positives

• Net sales increased by 9% in Q2 2025, indicating strong business performance.
• Organic revenue growth of 9% demonstrates underlying strength in the company's core business.
• The Diagnostics and Spatial Biology segment's 12% sales increase highlights successful expansion in key growth areas.
• Net earnings increased for the quarter, driven by volume leverage and a non-recurring prior year impairment of a business held-for-sale.
• The company is managing its capital structure effectively, as evidenced by its ability to fund investments, capital expenditures, and dividends.
• The company expects capital expenditures for the remainder of fiscal 2025 to be approximately $20 million.
• The company declared a cash dividend of $0.08 per share payable February 28, 2025.

Negatives

• Net earnings decreased for the six months ended December 31, 2024, primarily due to restructuring and restructuring-related costs.
• Gross margins decreased from 65.8% to 64.3% for the six months ended December 31, 2024.
• The company invested $15 million in Spear Bio during the six months ended December 31, 2024.

Risks

• The company's future performance is subject to risks related to integrating acquired businesses, introducing new products, and general economic conditions.
• Fluctuations in foreign currency exchange rates could impact future results.
• The company faces risks related to reliance on internal manufacturing, supply chain challenges, and maintaining intellectual property rights.
• The company faces risks related to credit risk and fluctuation in the market value of the company's investment portfolio, and unseen delays and expenses related to facility construction and improvements.

Future Outlook

Management expects to meet cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through available cash, cash generated from operations, and remaining credit on its revolving line of credit. The second option payment of approximately $1 billion plus potential contingent consideration to acquire the remaining 80.1% of Wilson Wolf is forecasted to occur between fiscal 2026 and fiscal 2028.

Management Comments

• The Company's strategic pillars for long-term growth and profitability are to grow and leverage the core, capitalize on high potential markets, market expansion through innovation and acquisition, deliver best-in-class customer experience, and develop people through a transformative culture.

Industry Context

Bio-Techne operates in the biotechnology reagents, instruments, and services market, serving both research and clinical diagnostic sectors. The company's performance reflects trends in these markets, including the increasing demand for spatial biology solutions and cell and gene therapy workflows. The company's strategic acquisitions, such as Lunaphore Technologies SA, are aimed at strengthening its position in these growing areas.

Comparison to Industry Standards

• The report does not provide enough information to make a detailed comparison to industry standards.
• A full comparison would require benchmarking against competitors like Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies, considering metrics such as organic growth rate, gross margin, R&D spending as a percentage of revenue, and return on invested capital.
• Additionally, comparing Bio-Techne's performance in specific segments like spatial biology and cell and gene therapy against specialized players in those areas would provide a more granular assessment.

Legal Proceedings

• As of February 6, 2025, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

Stakeholder Impact

• Shareholders will benefit from the increased net sales and continued dividend payments.
• Employees may be impacted by restructuring activities, but the company's growth strategy could create new opportunities.
• Customers will benefit from the company's focus on innovation and high-quality products.
• Suppliers may see increased demand as the company expands its operations.

Next Steps

• The company will continue to execute its strategic pillars for long-term growth and profitability.
• The company will focus on integrating acquired businesses and introducing new products.
• The company will monitor and manage risks related to economic conditions, competition, and supply chain challenges.

Key Dates

Keywords

Bio-Techne, Net Sales, Diagnostics, Spatial Biology, Protein Sciences, Organic Revenue, Restructuring, Acquisition, Dividend